Redwood Pharma AB

As of September 30, 2023, Redwood Pharma AB has 3.20M shares outstanding.

These figures are as of September 30, 2023.

As of September 30, 2023, Redwood Pharma AB maintains a current ratio of 8.90, meaning it holds 8.9x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended September 30, 2023, Redwood Pharma AB posted a negative return on equity (ROE) of -173.34, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -125.90, reflecting losses generated across the asset base.

These figures cover the twelve months ended September 30, 2023. Free cash flow yield is negative at -92.61: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -144.62, meaning Redwood Pharma AB raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Redwood Pharma AB's most recent stock split took place on August 22, 2023 with a 500:547 split ratio.

As of September 30, 2023, Redwood Pharma AB has an Altman Z-Score of 6.23, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.